Detalhe da pesquisa
1.
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma.
Blood
; 137(23): 3272-3276, 2021 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33534891
2.
Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.
Haematologica
; 2023 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38031807
3.
Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma.
Haematologica
; 106(10): 2667-2672, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32732355
4.
Safety of CAR T-cell therapy in kidney transplant recipients.
Blood
; 137(18): 2558-2562, 2021 05 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33512386
5.
Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection.
Blood
; 133(26): 2800-2802, 2019 06 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-31101626
6.
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline.
J Clin Oncol
; 39(35): 3978-3992, 2021 12 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34724386
7.
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.
J Clin Oncol
; 39(36): 4073-4126, 2021 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34724392
8.
Recognizing and Grading CAR T-Cell Toxicities: An Advanced Practitioner Perspective.
Front Oncol
; 10: 885, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32670871
9.
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma.
J Immunother Cancer
; 8(2)2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33361336
10.
Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma.
Blood Adv
; 4(13): 2871-2883, 2020 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-32589728
11.
Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma.
Blood Adv
; 4(16): 3943-3951, 2020 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32822484
12.
The Role of Advanced Practitioners in Optimizing Clinical Management and Support of Patients With Cytokine Release Syndrome From CAR T-Cell Therapy.
J Adv Pract Oncol
; 10(8): 833-843, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-33425467
13.
CAR T-Cell Therapy: Adverse Events and Management.
J Adv Pract Oncol
; 10(Suppl 3): 21-28, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-33520343
14.
Adult Survivorship: Considerations Following CAR T-Cell Therapy.
Clin J Oncol Nurs
; 23(2): 42-48, 2019 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30880816
15.
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
Nat Rev Clin Oncol
; 15(1): 47-62, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28925994
16.
A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma.
Blood Adv
; 7(21): 6785-6789, 2023 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37389847
17.
Success factors in the long-term sustainability of a telediabetes programme.
J Telemed Telecare
; 10(2): 84-8, 2004.
Artigo
em Inglês
| MEDLINE | ID: mdl-15068643
18.
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'.
Nat Rev Clin Oncol
; 15(4): 218, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29434334
19.
A preoperative intervention for pain reduction, improved mobility, and self-efficacy.
Appl Nurs Res
; 15(3): 174-83, 2002 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-12173168